

## Accepted Manuscript

Title: Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses

Authors: Bianca van Veggel, Adrianus J. de Langen, Sayed Hashemi, Kim Monkhorst, Efraim H. Rosenberg, Daniëlle A.M. Heideman, Teodora Radonic, Egbert F. Smit



PII: S0169-5002(18)30493-8  
DOI: <https://doi.org/10.1016/j.lungcan.2018.07.030>  
Reference: LUNG 5730

To appear in: *Lung Cancer*

Received date: 11-5-2018  
Revised date: 5-7-2018  
Accepted date: 20-7-2018

Please cite this article as: van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF, Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses, *Lung Cancer* (2018), <https://doi.org/10.1016/j.lungcan.2018.07.030>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses**

**Authors list**

Bianca van Veggel<sup>a</sup>; Adrianus J. de Langen<sup>a</sup>; Sayed Hashemi<sup>b</sup>; Kim Monkhorst<sup>c</sup>; Efraim H. Rosenberg<sup>c</sup>; Daniëlle A.M. Heideman<sup>d</sup>; Teodora Radonic<sup>d</sup>; Egbert F. Smit<sup>a,b</sup>

<sup>a</sup>Dept of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

<sup>b</sup>Dept of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

<sup>c</sup>Dept of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, The Netherlands

<sup>d</sup>Cancer Center Amsterdam, Dept of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

**Corresponding author**

Bianca van Veggel, Dept of Thoracic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands, tel: +31-20-5122958, b.v.veggel@nki.nl

**Highlights**

- Crizotinib treatment results in short-lasting responses.
- Heterogeneous responses, possibly due to subclonality of cMET driven resistance.
- Poor prognosis after cMET amplification as acquired resistance mechanism.

**Abstract**

**Purpose**

Download English Version:

<https://daneshyari.com/en/article/8453579>

Download Persian Version:

<https://daneshyari.com/article/8453579>

[Daneshyari.com](https://daneshyari.com)